Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

Cited by (1,000)

Items 401–500 of 1,000

1. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study
   Xiaojie Wu, Nanyang Li, Guoqin Wang, Wei Yong Liu, Jicheng Yu, Guoying Cao, Jingjing Wang, Yuancheng Chen, Juan Ma, Jufang Wu et al. · 2021 · Antimicrobial Agents and Chemotherapy
2. Event-Based Surveillance of Poisonings and Potentially Hazardous Exposures over 12 Months of the COVID-19 Pandemic
   Meghan A. Cook, Nicholas Brooke · 2021 · International Journal of Environmental Research and Public Health
3. Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm
   Nelli Morgulchik, Foteini Athanasopoulou, Edmund Chu, Yoriko Lam, Nazila Kamaly · 2021 · Interface Focus
4. Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies
   Elisa Souza Vaz, Sandra V. Vassiliades, Jeanine Giarolla, Michelle Carneiro Polli, Roberto Parise‐Filho · 2023 · European Journal of Clinical Pharmacology
5. Potential Fast COVID-19 Containment With Trehalose
   Daisy Martinon, Vanessa Borges, Angela C. Gomez, Kenichi Shimada · 2020 · Frontiers in Immunology
6. Safety perspectives on presently considered drugs for the treatment of COVID‐19
   Sophie L. Penman, Robyn T. Kiy, Rebecca L. Jensen, Christopher Beoku Betts, Ana Alfirevic, David J. Back, Saye Khoo, Andrew Owen, Munir Pirmohamed, B. Kevin Park et al. · 2020 · British Journal of Pharmacology
7. Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study
   Qiang Wang, Haipeng Guo, Li Yu, Xiangdong Jian, Xinguo Hou, Ning Zhong, Jianchun Fei, Dezhen Su, Zhou‐Yan Bian, Yi Zhang et al. · 2021 · Frontiers in Pharmacology
8. COVID-19 in dialysis patients: adding a few more pieces to the puzzle
   Talat Alp Ikizler · 2020 · Kidney International
9. Brazilian science under continuous attack
   Bernardo Galvão-Castro, Renato Sérgio Balão Cordeiro, Samuel Goldenberg · 2021 · The Lancet
10. Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk
    Joost Allard Offerhaus, Arthur A.M. Wilde, Carol Ann Remme · 2020 · Heart Rhythm
11. Cell and Animal Models for SARS-CoV-2 Research
    Eloïne Bestion, P. Halfon, S. Mezouar, J. Mege · 2022 · Viruses
12. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?
    Itsuro Kazama · 2020 · Drug Discoveries & Therapeutics
13. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach
    Katarina Baralić, Dragica Jorgovanović, Katarina Živančević, Evica Antonijević Miljaković, Biljana Antonijević, Aleksandra Buha Djordjević, Marijana Ćurčić, Danijela Đukić-Ćosić · 2020 · Toxicology and Applied Pharmacology
14. Response to: ‘Correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour et al
    Alexis Mathian, Zahir Amoura · 2020 · Annals of the Rheumatic Diseases
15. Past, present, and future of COVID-19: a review
    Camila Malta Romano, Alberto Chebabo, José Eduardo Levi · 2020 · Brazilian Journal of Medical and Biological Research
16. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients
    Nijad Bakhshaliyev, Mahmut Uluganyan, Asım Enhoş, Erdem Karaçöp, Ramazan Özdemir · 2020 · Journal of Electrocardiology
17. Efficacy of various treatment modalities for nCOV‐2019: A systematic review and meta‐analysis
    Shubham Misra, Manabesh Nath, Vijay Hadda, Deepti Vibha · 2020 · European Journal of Clinical Investigation
18. Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic
    Martin Helmut Stradner, Christian Dejaco, Jochen Zwerina, Ruth D. E. Fritsch-Stork · 2020 · Frontiers in Medicine
19. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study
    Raphaël Borie, Laurent Savale, Antoine Dossier, Jade Ghosn, Camille Taillé, Benoît Visseaux, Kamel Jebreen, Abourahmane Diallo, Chloé Tesmoingt, Lise Morer et al. · 2020 · PLoS ONE
20. Hydroxychloroquine for treatment of nonsevere COVID‐19 patients: Systematic review and meta‐analysis of controlled clinical trials
    Hozaifa Khalil Elsawah, Mohamed Ahmed Elsokary, Mahmoud Elrazzaz, Ahmed Hanei Elshafie · 2020 · Journal of Medical Virology
21. The Role of Regional Anesthesia During the SARS-CoV2 Pandemic: Appraisal of Clinical, Pharmacological and Organizational Aspects
    Gianluca Cappelleri, Andrea Fanelli, Daniela Ghisi, Gianluca Russo, Antonio Giorgi, Vito Torrano, Giuliano Lo Bianco, Salvatore Salomone, Roberto Fumagalli · 2021 · Frontiers in Pharmacology
22. A Comprehensive Updated Review on SARS‐CoV‐2 and COVID‐19
    Yunzhao R. Ren, Amit Golding, Alfred F. Sorbello, Ping Ji, Jianmeng Chen, Bhawana Saluja, Kimberly A. Witzmann, Vikram Arya, Kellie S. Reynolds, Suyoung Choi et al. · 2020 · The Journal of Clinical Pharmacology
23. Avaliação de tecnologias em saúde: tensões metodológicas durante a pandemia de Covid-19
    Carmen Romero, Julio Silva, Rodolfo Castro, Marcelo Ribeiro Alves, Carolina Mendes Franco · 2020 · Estudos Avançados
24. Care for Patients With Neuromuscular Disorders in the COVID-19 Pandemic Era
    Yung-Hao Tseng, Tai‐Heng Chen · 2021 · Frontiers in Neurology
25. Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro
    Yong Ni, Jinbiao Liao, Zhenlong Qian, Chunxiu Wu, Xiangyu Zhang, Ji Zhang, Youhua Xie, Sheng Jiang · 2021 · Bioorganic & Medicinal Chemistry
26. A review of potential treatments to date in COVID-19 patients according to the stage of the disease
    Tamim Alsuliman, Lugien Alasadi, Banan Alkharat, Micha Srour, Ali Alrstom · 2020 · Current Research in Translational Medicine
27. Overview of the Pathogenesis and Treatment of SARS-CoV-2 for Clinicians: A Comprehensive Literature Review
    Christian Voto, Paul D. Berkner, Carol A. Brenner · 2020 · Cureus
28. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications
    Ohad Oren, Eric H. Yang, Ty J. Gluckman, Erin D. Michos, Roger Scott Blumenthal, Bernard John Gersh · 2020 · Circulation Arrhythmia and Electrophysiology
29. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
    Patrick Brest, Jonathan Benzaquen, Daniel J. Klionsky, Paul M Hofman, Baharia Mograbi · 2020 · Autophagy
30. Current status of COVID-19 pandemic; characteristics, diagnosis, prevention, and treatment
    Shahrzad Ahangarzadeh, Zary Nokhodian, Mohammad Mehdi Ranjbar, Parto Nasri, Nazila Kassaian, Parisa Shoaei, Bahareh Vakili, Soodabeh Rostami, Abbas Alibakhshi, Fatemeh Yarian et al. · 2020 · Journal of Research in Medical Sciences
31. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
    Rahmet Güner, İmran Hasanoğlu, Bircan Kayaaslan, Adalet Aypak, Esragül Akıncı, Hürrem Bodur, Fatma Eser, Ayşe Kaya Kalem, Orhan Küçükşahin, İhsan Ateş et al. · 2020 · Journal of Infection and Public Health
32. Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19
    Dingzhong Li, Jianbing Hu, Dian Li, Weijun Yang, Shuang‐Feng Yin, Renhua Qiu · 2021 · Topics in Current Chemistry
33. Aminoquinolines as Translational Models for Drug Repurposing: Anticancer Adjuvant Properties and Toxicokinetic-Related Features
    Paulo Michel Pinheiro Ferreira, José Roberto de Oliveira Ferreira, Rayran Walter Ramos de Sousa, Daniel Pereira Bezerra, Gardênia Carmen Gadelha Militão · 2021 · Journal of Oncology
34. The epidemiology and therapeutic options for the COVID-19
    Jingwei Li, Jun Shao, Chengdi Wang, Weimin Li · 2020 · Precision Clinical Medicine
35. Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update
    Puja Kumari, Kajal Rawat, Lekha Saha · 2020 · Current Pharmacology Reports
36. Provision of ECPR during COVID-19: evidence, equity, and ethical dilemmas
    Elliott T Worku, Denzil J. Gill, Daniel Brodie, Roberto Lorusso, Alain Combes, Kiran Shekar · 2020 · Critical Care
37. Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results
    Alexandre Lopez, Gary Duclos, Bruno Pastène, Karine Bézulier, Romain Guilhaumou, Caroline Solas, Laurent Zieleskiewicz, Marc Léone · 2020 · International Journal of Antimicrobial Agents
38. The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents
    Gustavo Roberto Villas Boas, Vanessa Cristina Rescia, Marina Meirelles Paes, Stefânia Neiva Lavorato, Manoel F. de Magalhães-Filho, Mila Silva Cunha, Rafael da Conceição Simões, Roseli Boerngen de Lacerda, Renilson S. de Freitas-Júnior, Bruno Henrique da Silva Ramos et al. · 2020 · Molecules
39. FDALabel for drug repurposing studies and beyond
    Fang, Hong, Harris, Stephen, Liu, Zhichao, Thakkar, Shraddha, Yang, Junshuang, Ingle, Taylor, Xu, Joshua, Lesko, Lawrence, Rosario, Lilliam, Tong, Weida · 2020 · Nature Biotechnology
40. Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis
    Roberto Ariel Abeldaño Zúñiga, Silvia Mercedes Coca, Giuliana Florencia Abeldaño, Ruth Ana María González Villoria · 2021 · Therapeutic Advances in Respiratory Disease
41. Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates
    Sajad Fakhri, Zeinab Nouri, Seyed Zachariah Moradi, Esra Küpeli Akkol, Sana Piri, Eduardo Sobarzo‐Sánchez, Mohammad Hosein Farzaei, Javier Echeverría · 2021 · Molecules
42. Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?
    Benjamin Davido, Thibaud Lansaman, Simon Bessis, Christine Lawrence, Jean‐Claude Alvarez, Hélène Mascitti, Frédérique Bouchand, Pierre Moine, Véronique Perronne, Aurélie Le Gal et al. · 2020 · medRxiv · Retracted
43. Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era
    Moussa Abbas Saleh, James Kiernan Gabriels, David Chang, Joanna Stein Fishbein, Michael Qiu, Stavros Mountantonakis, Laurence Mark Epstein · 2020 · Circulation Arrhythmia and Electrophysiology
44. Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study
    Henry D. Huang, Hani M. Jneid, Mariam S. Aziz, Venkatesh Ravi, Parikshit S. Sharma, Timothy R. Larsen, Neal A. Chatterjee, Basil Saour, Zaid A. Aziz, Hemal M. Nayak et al. · 2020 · Cardiology and Therapy
45. Identification and Development of Therapeutics for COVID-19
    Halie M. Rando, Nils Wellhausen, Soumita Ghosh, Alexandra J. Lee, Anna Ada Dattoli, Fengling Hu, James Brian Byrd, Diane N. Rafizadeh, Ronan Lordan, Yanjun Qi et al. · 2021 · mSystems
46. Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study
    Mohammud M Alam, Saborny Mahmud, Sandeep Aggarwal, Sawsan Fathma, Naim Al Mahi, Mohammed S Shibli, Siddiqi M Haque, Sharothy Mahmud, Ziauddin Ahmed · 2021 · Cureus
47. Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
    Shota Yanagida, Ayano Satsuka, Sayo Hayashi, Atsushi Ono, Yasunari Kanda · 2021 · Toxicological Sciences
48. Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept
    Urs Thomet, Bogdan P. Amuzescu, Thomas Knott, Stefan A. Mann, Kanigula Mubagwa, Beatrice Mihaela Radu · 2021 · European Journal of Pharmacology
49. SARS-CoV-2 receptor binding domain radio-probe: a non-invasive approach for angiotensin-converting enzyme 2 mapping in mice
    Dan Li, Jin Ding, Te-li Liu, Feng Wang, Xiangxi Meng, Song Liu, Zhi Yang, Hua Zhu · 2021 · Acta Pharmacologica Sinica
50. Clinical update on COVID-19 for the emergency and critical care clinician: Medical management
    Brit Long, Summer Chavez, Brandon M Carius, William J. Brady, Stephen Y. Liang, Alex Koyfman, Michael A. Gottlieb · 2022 · The American Journal of Emergency Medicine
51. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines
    Joana Vitte, Moïse Michel, Soraya Mezouar, Aïssatou Bailo Diallo, Asma Fatima Boumaza, Jean‐Louis Mège, Benoît Desnues · 2020 · Frontiers in Immunology
52. A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management
    Muhammad Harris Shoaib, Farrukh Rafiq Ahmed, Muhammad Sikandar, Rabia Ismail Yousuf, Muhammad Talha Saleem · 2021 · Frontiers in Pharmacology
53. Drug-Based Therapeutic Strategies for COVID-19-Infected Patients and Their Challenges
    Khatereh Zarkesh, Elaheh Entezar-Almahdi, Parisa Ghasemiyeh, Mohsen Akbarian, Marzieh Bahmani, Shahrzad Roudaki, Rahil Fazlinejad, Soliman Mohammadi‐Samani, Negar Firouzabadi, Majid Hosseini et al. · 2021 · Future Microbiology
54. Hydroxychloroquine: mechanism of action inhibiting SARS-CoV2 entry
    Zixuan Yuan, Mahmud Arif Pavel, Hao Wang, Sonja Hansen · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
55. Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues
    Wong, Andy On-Tik, Gurung, Bimal, Wong, Wing Sum, Mak, Suet Yee, Tse, Wan Wai, Li, Chloe M., Lieu, Deborah K., Costa, Kevin D., Li, Ronald A., Hajjar, Roger J. · 2021 · Journal of Molecular and Cellular Cardiology
56. Insights in Chloroquine Action: Perspectives and Implications in Malaria and <scp>COVID</scp>‐19
    Pillat, Micheli Mainardi, Krüger, Arne, Guimarães, Lara Mendes Ferreira, Lameu, Claudiana, de Souza, Edmarcia Elisa, Wrenger, Carsten, Ulrich, Henning · 2020 · Cytometry Part A
57. Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
    Vitória Andrade Palmeira, Larissa Braga Costa, Lucas Giandoni Perez, Victor Teatini Ribeiro, Katharina Lanza, Ana Cristina Simões e Silva · 2020 · Clinics
58. Fármacos prometedores y potenciales para el tratamiento de COVID-19
    Carlos Moneriz, Cristian Castro-Salguedo · 2020 · Revista chilena de infectología
59. Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid)
    Bahaa Abu-Raya, Giovanni Battista Migliori, Miguel O’Ryan, Kathryn M. Edwards, Antoní Torres, Jan‐Willem C. Alffenaar, Anne‐Grete Märtson, Rosella Centis, Lia D’Ambrosio, Katie L. Flanagan et al. · 2020 · Frontiers in Medicine
60. A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital
    Bharat D. Purandare, Prasad Anant Rajhans, Sameer Jog, Parikshit Shirish Prayag, Harshwardhan Pawar, Vikram L Narasimhan, Gauri Oak, Amruta Bedekar, Prasad Vasant Akole, Shailaja Chavan et al. · 2020 · Indian Journal of Critical Care Medicine
61. SARS‐CoV‐2 infection of polarized human airway epithelium induces necroptosis that causes airway epithelial barrier dysfunction
    Siyuan Hao, Kang Ning, Çağla Aksu Küz, Min Xiong, Wei Zou, Soo Yuen Park, Shane McFarlin, Ziying Yan, Jianming Qiu · 2023 · Journal of Medical Virology
62. Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review
    Yogesh Acharya, Abida Sayed · 2020 · Therapeutic Advances in Infectious Disease
63. The scientific production during 2009 swine flu pandemic and 2019/2020 COVID-19 pandemic
    Tatiana Aline Carvalho, Tamires Monteiro Lima, Vitória Franchini Melani, Matheus Ferreira Mendes, Larissa Renata dos Santos Pereira, Fernando Augusto Lima Marson · 2020 · Pulmonology
64. Cardiovascular Pathophysiology, Epidemiology, and Treatment Considerations of Coronavirus Disease 2019 (COVID-19): A Review
    Jeremy Y. Levett, Valeria Raparelli, Vartan Mardigyan, Mark Jeffrey Eisenberg · 2020 · CJC Open
65. Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19
    Norma Francenia Santos-Sánchez, Raúl Salas-Coronado · 2020 · Medwave
66. Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis
    Sourabh Agstam, Ashutosh Yadav, Praveen M Kumar, Ankur Gupta · 2020 · Indian Pacing and Electrophysiology Journal
67. A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment
    Chuanfeng Tang, Hong Ding, Yang Sun, Zhujun Han, Lingdong Kong · 2021 · Annals of Palliative Medicine
68. COVID-19 and Coronaviral Hepatitis: Evidence of Collateral Damage
    Mohammad Khalid Parvez · 2020 · Future Virology
69. Progresses in clinical studies on antiviral therapies for COVID‐19—Experience and lessons in design of clinical trials
    Getu Zhaori, Lu Lu, Chunyan Liu, Yongli Guo · 2020 · Pediatric Investigation
70. Ongoing COVID-19 Pandemic: A Concise but Updated Comprehensive Review
    Chao Wang, Xiong Xiao, Hongyan Feng, Zheng‐Yuan Hong, Meng Li, Ning Tu, Xuerong Li, Ke Wang, Lihong Bu · 2021 · Current Microbiology
71. Design, Synthesis, and Development of 4‐[(7‐Chloroquinoline‐4‐yl)amino]phenol as a Potential SARS‐CoV‐2 Mpro Inhibitor
    James O. Guevara‐Pulido, Ronald A. Jiménez, Sandra Johanna Morantes, Deissy N. Jaramillo, Paola Acosta‐Guzmán · 2022 · ChemistrySelect
72. Prevalence of comorbidities and symptoms stratified by severity of illness amongst adult patients with COVID-19: a systematic review
    Ritambhara Pandey, Devesh Rai, Muhammad Tahir, Abdul Wahab, Dhrubajyoti Bandyopadhyay, Emil Patrick Lesho, Maryrose R Laguio-Vila, Emilio Fentanes, Raseen Tariq, Srihari S. Naidu et al. · 2022 · Archives of Medical Science - Atherosclerotic Diseases
73. Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19
    Waquar Ahsan, Hassan A. Alhazmi, Kuldeep Patel, Bharti Mangla, Mohammed Al Bratty, Shamama Javed, Asim Najmi, Muhammad H. Sultan, Hafiz Antar Makeen, Asaad Khalid et al. · 2020 · Frontiers in Public Health
74. Systemic immunosuppression in times of COVID‐19: Do we need to rethink our standards?
    Stephan Grabbe, Stefan Beissert, Alexander Enk · 2020 · JDDG Journal der Deutschen Dermatologischen Gesellschaft
75. Quinoline-based Compounds as Key Candidates to Tackle Drug Discovery Programs of Microbicidal Agents
    Aline Nefertiti Silva da Gama, Maria de Nazaré Correia Soeiro · 2020 · Current Pharmaceutical Design
76. Antivirals for COVID-19 in Solid Organ Transplant Recipients
    Justin C. Laracy, Elizabeth C. Verna, Marcus R. Pereira · 2020 · Current Transplantation Reports
77. Gender differences in treatment of Coronavirus Disease-2019
    Immacolata Ambrosino, Elena Barbagelata, Graziamaria Corbi, Tiziana Ciarambino, Cecilia Politi, Anna Maria Moretti · 2020 · Monaldi Archives for Chest Disease
78. Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design
    Daojiong Wang, Yushu Ge, Bin Zhong, Dan Liu · 2021 · Computational and Structural Biotechnology Journal
79. Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2
    Julia Werner, Raphael M. Kronberg, Paweł Stachura, Philipp Niklas Ostermann, Lisa Müller, Heiner Schaal, Sanil Bhatia, Jakob Nikolas Kather, Arndt Borkhardt, Aleksandra A. Pandyra et al. · 2021 · Viruses
80. Lung-on-chip microdevices to foster pulmonary drug discovery
    Yashi Sisodia, Komal Shah, Adil Ali Sayyed, Meenakshi Jain, Syed Ansar Ali, Piyush Gondaliya, Kiran Kalia, Rakesh Kumar Tekade · 2022 · Biomaterials Science
81. COVID ‐19 and toxicity from potential treatments: Panacea or poison
    Anselm Wong · 2020 · Emergency Medicine Australasia
82. Abstracts for reports of randomized trials of COVID-19 interventions had low quality and high spin
    Dongguang Wang, Lingmin Chen, Lian Wang, Fang Hua, Juan Li, Yuxi Li, Yonggang Zhang, Hong Song Fan, Weimin Li, Mike J Clarke · 2021 · Journal of Clinical Epidemiology
83. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time
    Benjamin Davido, Ghilas Boussaïd, Isabelle Vaugier, Thibaud Lansaman, Frédérique Bouchand, Christine Lawrence, Jean‐Claude Alvarez, Pierre Moine, Véronique Perronne, Frédéric Barbot et al. · 2020 · International Journal of Antimicrobial Agents
84. Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis
    Teodoro J. Oscanoa, Xavier Vidal, Jørgen Kim Kanters, Román Romero‐Ortuño · 2020 · International Journal of Antimicrobial Agents
85. SARS-CoV-2 Aiming for the Heart: A Multicenter Italian Perspective About Cardiovascular Issues in COVID-19
    Matteo Briguglio, Mauro Porta, Francesca Zuffada, Alberto R. Bona, Tiziano Crespi, Fabio Pino, Paolo Perazzo, Marco Mazzocchi, Riccardo Giorgino, Giuseppe De Angelis et al. · 2020 · Frontiers in Physiology
86. SARS-CoV-2 As an Inflammatory Cardiovascular Disease: Current Knowledge and Future Challenges
    Kevin Shah, M. Elizabeth Hammond, Stavros George Drakos, Jeffrey L. Anderson, James Chen-Tson Fang, Kirk U. Knowlton, Robin M. Shaw · 2021 · Future Cardiology
87. Adapting for the COVID-19 pandemic in Ecuador, a characterization of hospital strategies and patients
    Daniel Garzón-Chávez, Daniel Romero-Álvarez, Marco Bonifaz-Valverde, Juan Gaviria, Daniel Mero, Narcisa Gunsha, Asiris Perez, María Garcia, Hugo Espejo, Franklin Espinosa et al. · 2021 · PLoS ONE
88. Major royal jelly proteins elicited suppression of SARS-CoV-2 entry and replication with halting lung injury
    Marwa Muhammad Abu-Serie, Noha H. Habashy · 2022 · International Journal of Biological Macromolecules
89. Water resource rejuvenation via AOP based degradation of pharmaceuticals extensively used during COVID-19
    Vineeta Singh, Shashi Prakash Gupta, Sujoy Kumar Samanta · 2024 · Journal of Water Process Engineering
90. Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer
    Tristan E. Knight · 2020 · Biopreservation and Biobanking
91. A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19
    Nowair Hussain, Emily Chung, Jonathan Heyl, Bisma Hussain, Michael Oh, Candis Pinon, Soumya Boral, David Chun, Benson Babu · 2020 · Cureus
92. Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)
    Emili Dı́az, R. Amézaga Menéndez, P. Vidal Cortés, María Gero Escapa, Borja Suberviola, A. Serrano Lázaro, Pilar Marcos-Neira, Manuel Quintana‐Díaz, M. Catalán González · 2021 · Medicina Intensiva (English Edition)
93. Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine
    David J. Whittaker, Rebecca A. Capel, Maurice Hendrix, Xin Hui S Chan, Neil Herring, Nicholas John White, Gary R. Mirams, Rebecca A.B. Burton · 2021 · Royal Society Open Science
94. Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality
    Kimia Honarmand, J.B. Penn, Arnav Agarwal, Reed Alexander Cunningham Siemieniuk, Romina Brignardello‐Petersen, Jessica Julia Bartoszko, Dena Zeraatkar, Thomas Agoritsas, Karen E. A. Burns, Shannon M. Fernando et al. · 2021 · Journal of Clinical Epidemiology
95. Applying polypharmacology approach for drug repurposing for SARS-CoV2
    Esther Jamir, Himakshi Sarma, Lipsa Priyadarsinee, Selvaraman Nagamani, Kikrusenuo Kiewhuo, Anamika Singh Gaur, Ravindra Kumar Rawal, N. Arul Murugan, V. Subramanian, Garikapati Narahari Sastry · 2022 · Journal of Chemical Sciences
96. Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection
    Muhammad Aslam, Yury V. Ladilov · 2020 · Cells
97. Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis
    Tomasz Chroboczek, Marie Lacoste, Chloé Wackenheim, Thibaut Challan-Belval, Benjamin Amar, Thomas Boisson, Jason Hubac, Dominique Leduc, Colleen Masse, Victor Dechaene et al. · 2020 · medRxiv
98. COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias
    Lia Crotti, Elena Arbelo · 2020 · Heart Rhythm
99. Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19
    Allan Giri, Ankita Das, Ajoy Krishna Sarkar, Ashok Kumar Giri · 2020 · Genes and Environment
100. Current treatment of COVID-19 in renal patients: hope or hype?
     Roberto Palumbo, Francesco Londrino, Emanuela Cordova, Giorgia Gambardella, Pasquale Niscola, Sara Dominijanni · 2020 · Internal and Emergency Medicine